

# Stereoselectivity in the organoiron-mediated synthesis of (±)-mesembrine

Caroline Roe<sup>a</sup>, Elizabeth J. Sandoe<sup>a</sup>, G. Richard Stephenson<sup>a,\*</sup>, Christopher E. Anson<sup>b</sup>

<sup>a</sup> Wolfson Materials and Catalysis Centre, School of Chemical Sciences and Pharmacy University of East Anglia, Norwich NR4 7TJ, UK

<sup>b</sup> Institut für Anorganische Chemie der Universität Karlsruhe, Engesserstrasse 15, D-76128 Karlsruhe, Germany

Received 27 September 2007; revised 9 November 2007; accepted 22 November 2007

## Abstract

The preparation and structural characterisation of a 1-aryl-substituted electrophilic  $\eta^5$ -cyclohexadienyliron complex with the correct functionalisation as a 'C<sub>12</sub> building block' for the synthesis of (±)-mesembrine establishes the accessibility of a flattened conformation to allow nucleophile addition *ipso* to the arene. The chirality relay in quaternary centre formation by nucleophile addition has been confirmed, and the product has been converted into the *Sceletium* alkaloid mesembrine.

© 2007 Elsevier Ltd. All rights reserved.

**Keywords:** Asymmetric synthesis; Organometallic electrophiles; Tricarbonyliron; Mesembrine

The *Sceletium* alkaloid mesembrine (**1**)<sup>1</sup> is a naturally occurring serotonin uptake inhibitor<sup>2</sup> with a suitable structure to illustrate the utility of aryl-substituted<sup>3</sup> cyclohexadienyliron complexes as central 'C<sub>12</sub> building blocks'<sup>4</sup> in alkaloid synthesis (Fig. 1). The key structural feature of mesembrine is a saturated pyrrolidine ring fused to a cyclohexanone, with an aryl substituent directly attached to a quaternary centre at the ring fusion. This type of quaternary centre has attracted considerable attention as a synthetic target as it is common in a wide range of alkaloids,

particularly *Amaryllidaceae* alkaloids<sup>5</sup> such as crinine<sup>6,7</sup> and maritidine<sup>8,9</sup> which have more complex polycyclic structures. Recently, considerable advances<sup>10</sup> have been made to gain efficient access to structures of this type, which have important biological activity<sup>2,7,9,11</sup> and a suitable size and basicity to inspire the design of biomimetic pharmacophores.<sup>12</sup>

We have described<sup>3</sup> a generally applicable method to prepare synthetically important<sup>13</sup> electrophilic 1-aryl-substituted  $\eta^5$ -cyclohexadienyliron complexes from the 1,4-dimethoxycyclohexadienyliron complex **3** and have used the method to gain access to the 3',4'-methylenedioxy-substituted example **4**,<sup>3</sup> which has the correct substitution pattern for use as a C<sub>12</sub> building block for crinine (Scheme 1). A similar approach with a 2',3'-diether (electrophile **5**) has been used successfully<sup>14</sup> in our formal total synthesis of lycoramine. We describe here, the preparation of **2** and its use in a four-step<sup>15</sup> synthesis of (±)-mesembrine (six steps from **3**; nine steps from 1,4-dimethoxybenzene).

The preparation of the chiral electrophile **2** from its prochiral precursor tricarbonyl( $\eta^4$ -1,4-dimethoxycyclohexadiene)iron(0)<sup>3,16,17</sup> is an important example of the induction of asymmetry in multihapto complexes<sup>18</sup> and enantioselective





Fig. 1. Illustration of an example of arylcyclohexadienyliron electrophiles as C<sub>12</sub> building blocks in alkaloid synthesis.

\* Corresponding author. Tel.: +44 1603 592019; fax: +44 1603 592003.  
E-mail address: g.r.stephenson@uea.ac.uk (G.R. Stephenson).




Scheme 1. Examples of the preparation of 1-aryl-4-methoxycyclohexadienyliron electrophiles.

methods for hydride abstraction have been employed<sup>19</sup> in this step, using chiral analogues<sup>20</sup> of triphenylcarbenium ion reagents. Starting from **2**, the electrophilicity introduced into the ligand by the  $[\text{Fe}(\text{CO})_3]^+$  group is used in both the C–C bond formation steps that establish the chiral quaternary centre of the target structures. The sense of asymmetric induction depends on the order of the nucleophile addition reactions, and our short synthesis of ( $\pm$ )-mesembrine from **2** was undertaken in the racemic series to prove the relative stereochemistry of malononitrile enolate addition<sup>3,4,14,17</sup> to arylcyclohexadienyliron(1) complexes (i.e., introduction of the arene first, and the  $\text{CH}_2\text{CN}$  moiety second). The *exo*-stereochemistry of the  $\text{CH}_2\text{CN}$  substituent in the product<sup>21</sup> has been proved in this work, and crystallographic characterisation of both the electrophile and the malononitrile adduct are described.

The conditions and solvents used with aryllithium reagents in reactions of the type shown in Scheme 1 have been found to be crucial to obtain high yields, since competing addition at CO ligands is possible.<sup>22</sup> Our synthesis of ( $\pm$ )-mesembrine (Scheme 2) thus began with optimisation of the preparation<sup>23</sup> of 3,4-dimethoxyphenyllithium from 4-bromoveratrole, to check the compatibility with the solvent used, and the requirements of the organoiron-mediated step. The efficiency of lithium/bromine exchange was determined by trapping with trimethylsilyl chloride.

When the reaction was performed with *n*-butyllithium in diethyl ether at  $-30^\circ\text{C}$ ,<sup>24</sup> the corresponding arylsilane was obtained in  $>77\%$  yield. To prepare **6** (Scheme 2), after 10 min to complete the lithium/bromine exchange of 3,4-dimethoxybromobenzene, the reaction mixture was cooled to  $-78^\circ\text{C}$  and **3** was added in solution in dichloromethane.<sup>25</sup> Product **6** was obtained in 66% yield and converted into **2a** (55% yield) by reaction<sup>26</sup> with triphenylcarbenium tetrafluoroborate in dichloromethane. The alternative acid-mediated procedure<sup>27</sup> proved more efficient in this case, and using hexafluorophosphoric acid in acetic anhydride afforded **2b** in over 80% yield. The enolate was generated from 2-trimethylsilyl ethyl cyanoethanoate by our standard method<sup>3,17</sup> and after addition to **2b**, the reaction was quenched with TBAF and heated at reflux for 3 h to effect an in situ desilylation/dealkoxylation/decarboxylation of the intermediate, giving access to the cyanomethyl adduct **7** in 77% yield in a single step.<sup>15</sup> Product **7** was crystallised from diethyl ether, and the relative stereochemistry of nucleophile addition to **2b** was proved by X-ray crystallography (Fig. 2b). The expected *exo* addition of the malononitrile was thus confirmed. Reduction with DIBAL in dichloromethane/diethyl ether was followed by the addition of ammonium bromide and methylamine in methanol, and then sodium borohydride (added in three portions as a solid) to allow direct access<sup>15</sup> to the secondary amine **8**, which was isolated in 79% yield. Decomplexation with anhydrous trimethylamine N-oxide<sup>28</sup> in acetone followed by quenching with oxalic acid (3 h at room temperature) and a basic work up afforded ( $\pm$ )-mesembrine (**1**) in 52% yield.<sup>29</sup>

The electrophilic  $\text{C}_{12}$  building block was crystallised from acetone by a two-well diffusion procedure (diethyl ether in the outer well). The structure (Fig. 2a) shows the expected orientation of the tricarbonyliron group, which has one CO ligand lying under the  $\text{CH}_2$  of the cyclohexadienyl ring. The  $\text{CH}_2$  group [C(6)] is also bent away from the principal plane of the haptile part of the ligand [C(1)–C(5)] in the normal way. Importantly, in the solid state structure, the dihedral angle between the plane of the arene and the dienyl ligand is relatively small ( $+39^\circ$ ),



Scheme 2. Organoiron-mediated synthesis of ( $\pm$ )-mesembrine.




Fig. 2. ORTEP drawings of the organometallic electrophile in **2b** (a) and the adduct **7** (b).

corresponding to the conformation needed to allow access of the malononitrile enolate to the *ipso*<sup>30</sup> electrophilic centre [C(1)]. The C(1)–C(8) bond length (1.479 Å) is consistent with significant  $\pi$  overlap between the arene and dienyl sections of the ligand, and it is proposed that the electron-rich nature of the aryl ether helps promote the flattening of the structure by promoting electron donation from the arene.

In conclusion, we have completed a short synthesis of ( $\pm$ )-mesembrine from the 1,4-dimethoxy salt **3** by a reaction sequence that makes multiple use of the metal, and have proved that chirality relay from the  $\eta^5$ -1-arylcyclohexadienyliron complex **2** promotes exclusive *exo* addition of the second nucleophile in the sequence. Complex **2** adopts a flattened conformation in solution to a sufficient extent to allow efficient nucleophilic addition *ipso* to the arene, and a solid state model for this conformation has been defined. Transfer of electron density from the aromatic ring to the cationic dienyliron moiety helps favour the required flattened structure despite free rotation of the arene. The naturally occurring oxidation patterns of the arenes of *Sceletium* and *Amaryllidaceae* alkaloids are thus shown to be advantageous in synthetic routes based on the organoiron C<sub>12</sub> building block<sup>3,4</sup> approach. Work is in progress towards the more advanced targets crinine<sup>3</sup> and maritidine<sup>32</sup> based on these methods.

#### Crystal data:

Compound **2b**: C<sub>19.75</sub>H<sub>21</sub>F<sub>6</sub>FeO<sub>6.5</sub>P, 563.19 g mol<sup>−1</sup>, *F*(000) 2292, *D*<sub>c</sub> 1.620 g cm<sup>−3</sup>,  $\mu$ (Mo-K $\alpha$ ) 0.808 mm<sup>−1</sup>, monoclinic, *C*2/*c*, *a* 23.652(3), *b* 13.9637(15), *c* 14.4029(15) Å,  $\beta$  103.940(2)°, *V* 4616.8(8) Å<sup>3</sup>, *T* 100 K; 9868 data, 4251 unique, *R*<sub>int</sub> 0.0486, 317 parameters, *wR*<sub>2</sub> 0.0949, *S* 0.995, *R*<sub>1</sub> (2317 with *I* > 2 $\sigma$ (*I*)) 0.0518, max. diff. peak/hole +0.53/−0.60 e Å<sup>−3</sup>.

Compound **7**: C<sub>20</sub>H<sub>19</sub>FeNO<sub>6</sub>, 425.21 g mol<sup>−1</sup>, *F*(000) 880, *D*<sub>c</sub> 1.480 g cm<sup>−3</sup>,  $\mu$ (Mo-K $\alpha$ ) 0.827 mm<sup>−1</sup>, monoclinic, *P*2<sub>1</sub>/*c*, *a* 8.9196(13), *b* 26.161(4), *c* 9.2714(14) Å,  $\beta$  118.070(2)°, *V* 1908.9(5) Å<sup>3</sup>, *T* 100 K; 8101 data, 4199 unique, *R*<sub>int</sub> 0.0291, 264 parameters, *wR*<sub>2</sub> 0.0857, *S* 0.990, *R*<sub>1</sub> (3269 with *I* > 2 $\sigma$ (*I*)) 0.0402, max. diff. peak/hole +0.63/−0.32 e Å<sup>−3</sup>.

#### Supplementary data

Crystallographic data (excluding structure factors) for the structures in this Letter have been deposited with the Cambridge Crystallographic Data Centre as Supplementary Publication Nos. CCDC 661648 and 661649. Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK: <http://www.ccdc.cam.ac.uk/cgi-bin/catreq.cgi>, e-mail: [data\\_request@ccdc.cam.ac.uk](mailto:data_request@ccdc.cam.ac.uk), or fax: +44 1223 336033.

#### Acknowledgements

The authors acknowledge the EPSRC, and Glaxo Smith Kline for financial support, and the EPSRC Mass Spectrometry Centre at the University of Wales, Swansea for high resolution mass spectrometric measurements.

#### References and notes

- Isolation from *Sceletium tortuosum*: Bodendorf, K.; Krieger, W. *Archiv. Pharm.* **1957**, *290*, 441–448; structure: Popelak, A.; Haack, E.; Lettenbauer, G.; Spingler, H. *Naturwissenschaften* **1960**, *47*, 156; Coggon, P.; Farrier, D. S.; Jeffs, P. W.; McPhail, A. T.; Gross, P. M. *J. Chem. Soc. B* **1970**, 1267–1271.
- Gericke, N. P.; Van Wyk, B. E. World Patent 9,746,234, 199; Gericke, N. P.; Van Wyk, B. E. *Chem. Abstr.* **1998**, *128*, 80030.
- Owen, D. A.; Malkov, A. V.; Palotai, I. M.; Roe, C.; Sandoe, E. J.; Stephenson, G. R. *Chem. Eur. J.* **2007**, *13*, 4293–4311.
- Malkov, A. V.; Auffrant, A.; Renard, C.; Rose, E.; Rose-Munch, F.; Owen, D. A.; Sandoe, E. J.; Stephenson, G. R. *Inorg. Chim. Acta* **1999**, *296*, 139–149.
- Jin, Z. *Nat. Prod. Rep.* **2007**, *24*, 886–905; Jin, Z. *Nat. Prod. Rep.* **2005**, *22*, 111–126; Prabhakar, S.; Tavares, M. R. *Alkaloids: Chem. Biol. Perspect.* **2001**, *15*, 433–572; Hoshino, O. In *The Alkaloids*; Cordell, G. A., Ed.; Academic Press: New York, 1998; Vol. 51, pp 324–424; the *Amaryllidaceae* alkaloids are still a rich source of new potentially biologically active target structures with substantial synthetic challenges: Unver, N. *Phytochem. Rev.* **2007**, *6*, 125–135.
- Mason, L. H.; Puschett, E. R.; Wildman, W. C. *J. Am. Chem. Soc.* **1955**, *77*, 1253–1256; Wildman, W. C. *J. Am. Chem. Soc.* **1958**, *80*, 2567–2575.
- Examples of the biological activity of crinine: (a) Elgorashi, E. E.; Stafford, G. I.; Jager, A. K.; van Staden, J. *Plant. Med.* **2006**, *72*, 470–473 (inhibition of [<sup>3</sup>H]citalopram binding to the rat brain serotonin

- transporter); Orhan, I.; Sener, B. *Acta Horticult.* **2005**, 678 (anticholinesterase activity in Alzheimer's disease patients).
8. Pacheco, P.; Silva, M.; Steglich, W.; Watson, W. H. *Rev. Latinoam. Quim.* **1978**, 9, 28–32; recent example (isolation from *Pancratium tortuosum* herb): J. Pharm. Sci. **2007**, 21, 61–68; structure: Zabel, V.; Watson, W. H.; Pacheco, P.; Silva, M. *Cryst. Struct. Commun.* **1979**, 8, 371–376.
  9. Examples of the biological activity of maritidine: Cea, G.; Alarcon, M.; Weigart, G. *Med. Sci.* **1986**, 14, 90 (clastogenic effect/mutagenic); see also Ref. 7a.
  10. For examples, see: Nemoto, H. *Chem. Pharm. Bull.* **2007**, 55, 961–974; Paul, T.; Malachowski, W. P.; Lee, J. *Org. Lett.* **2006**, 8, 4007–4010; Taber, D. F.; He, Y. *J. Org. Chem.* **2005**, 70, 7711–7714 (mesembrenone); Bru, C.; Guillou, C. *Tetrahedron* **2006**, 62, 9043–9048; Pearson, W. H.; Lovering, F. E. *J. Org. Chem.* **1998**, 53, 3607–3617; Martin, S. F.; Campbell, C. L. *J. Org. Chem.* **1998**, 53, 3184–3190 (crinine); Bru, C.; Thal, C.; Guillou, C. *Org. Lett.* **2003**, 5, 1845–1846 (maritidine); For our organoiron intermediate for crinine, see Ref. 3.
  11. For examples of biological activities of other *Amaryllidaceae* alkaloids, see: lycoramine: Han, S. Y.; Sweeney, J. E.; Bachman, E. S.; Schweiger, E. J.; Forloni, G.; Coyle, J. T.; Davis, B. M.; Joullie, M. M. *Eur. J. Med. Chem.* **1992**, 27, 673–687 (against Alzheimer's disease); Lopez, S.; Bastida, J.; Viladomat, F.; Codina, C. *Life Sci.* **2002**, 71, 2521–2529 (inhibition of acetylcholine esterase); lycorine: Nino, J.; Hincapie, G. M.; Correa, Y. M.; Mosquera, O. M. *Zeit. Naturforsch. C: J. Biosci.* **2007**, 62, 223–226 (topoisomerase inhibition); galanthamine: Weinstock, M. *CNS Drugs* **1999**, 11, 307–323 (treatment of Alzheimer's disease); Han, S. Y.; Sweeney, J. E.; Bachman, E. S.; Schweiger, E. J.; Forloni, G.; Coyle, J. T.; Davis, B. M.; Joullie, M. M. *Eur. J. Med. Chem.* **1992**, 27, 673–687 (reversible cholinesterase inhibitor).
  12. Sneider, W. E. *Drug Prototypes and Their Exploitation*; Wiley: Chichester, 1996.
  13. For Guillou's work employing the  $\text{Fe}(\text{CO})_2\text{Ph}_3$  analogue of **3**, see: (a) Guillou, C.; Millot, N.; Reboul, V.; Thal, C. *Tetrahedron Lett.* **1996**, 37, 4515–4518; the  $(\eta^5\text{-cyclohexadienyl})\text{iron}$  series is one of the most widely applied of this series of electrophiles, that span the hapticity range  $\eta^2\text{--}\eta^7$ ; (b) For a survey of organoiron complexes, see: Stephenson, G. R. *Organometallic Complexes of Iron*. In *Science of Synthesis*; Lautens, M., Ed.; Houben-Weyl Methods of Molecular Transformations; Georg Thieme Verlag: Stuttgart, 2001; Vol. 1, pp 745–886; for earlier reviews of the applications of the cyclohexadienyliron series, see: (c) Pearson, A. J. *Acc. Chem. Res.* **1980**, 13, 463–469; (d) Pearson, A. J. *Synlett* **1990**, 10–19; (e) Knölker, H.-J. *Synlett* **1992**, 371–387; (f) Donaldson, W. A. *Aldrichim. Acta* **1997**, 30, 17–24; (g) Knölker, H.-J.; Braier, A.; Brocher, D. J.; Cammerer, S.; Fröhner, W.; Gonser, P.; Hermann, H.; Herzberg, D.; Reddy, K. R.; Rohde, G. *Pure Appl. Chem.* **2001**, 73, 1075–1086.
  14. Sandoe, E. J.; Stephenson, G. R.; Swanson, S. *Tetrahedron Lett.* **1996**, 37, 6283–6286.
  15. We have developed one pot procedures to add the malononitrile nucleophile and then perform desilylation by addition of TBAF into the reactions mixture (conversion of **2b** into **7**) and for the reductive amination of the nitrile (conversion of **7** into **8**), see Scheme 2.
  16. Birch, A. J.; Cross, P. E.; Lewis, J.; White, D. A.; Wild, S. B. *J. Chem. Soc. A* **1968**, 332–340; see also Ref. 17.
  17. Stephenson, G. R.; Finch, H.; Owen, D. A.; Swanson, S. *Tetrahedron* **1993**, 49, 5649–5662.
  18. For a discussion of chirality in such complexes, see: Stephenson, G. R. In *Handbook of Functionalised Organometallics*; Knochel, P., Ed.; Wiley-VCH: Weinheim, 2005; pp 569–626.
  19. Magdziak, D.; Pettus, L. H.; Pettus, T. R. *Org. Lett.* **2001**, 3, 557–559; Older, J. E. J. PhD Thesis, University of East Anglia, 2001; Older, J. E. J.; Stephenson, G. R. unpublished results; ees up to about 40% have been achieved with first generation chiral trityl analogues.
  20. Chen, C. T.; Chao, S. D.; Yen, K. C. *J. Am. Chem. Soc.* **1997**, 119, 11341–11342; Chen, C. T.; Chao, S. D.; Yen, K. C. *Synlett* **1998**, 924–926; Chen, C. T.; Chao, S. D. *J. Org. Chem.* **1999**, 64, 1090–1091.
  21. The examples reported in this Letter were performed with racemic complexes.
  22. Malkov, A. V.; Stephenson, G. R. *J. Organomet. Chem.* **1995**, 489, C44–C47; see also Ref. 4.
  23. For the preparation of 3,4-dimethoxyphenyllithium from 3,4-dimethoxybromobenzene in THF at  $-78^\circ\text{C}$ , see: Meyers, A. I.; Avila, W. B. *J. Org. Chem.* **1981**, 46, 3881–3886; a procedure using 3,4-dimethoxyiodobenzene has also been reported: Capparelli, M. P.; DeSchepper, R. E.; Swenton, J. S. *J. Org. Chem.* **1987**, 52, 4953–4957.
  24. After 5 min to form the aryllithium reagent, the reaction mixture was cooled to  $-78^\circ\text{C}$  before addition of the trimethylsilyl chloride.
  25. For the use of dichloromethane for the addition of organolithium reagents to tricarbonyl( $\eta^5\text{-cyclohexadienyl})\text{iron}$  complexes, see: Birch, A. J.; Bogsányi, D.; Kelly, L. F. *J. Organomet. Chem.* **1981**, 214, C39–C42.
  26. Hudson, R. D. A.; Osborne, S. A.; Stephenson, G. R. *Tetrahedron* **1997**, 53, 4095–4104; Tranchier, J. P.; Chavignon, R.; Prim, D.; Aufrant, A.; Giner Planas, J.; Rose-Munch, F.; Rose, E.; Stephenson, G. R. *Tetrahedron Lett.* **2001**, 42, 3311–3313.
  27. Stephenson, G. R.; Owen, D. A.; Finch, H.; Swanson, S. *Aust. J. Chem.* **1992**, 45, 121–134; Howell, J. A. S.; Bell, A. G.; O'Leary, P. J.; Stephenson, G. R.; Hastings, M.; Howard, P. W.; Owen, D. A.; Whitehead, A. J.; McArdle, P.; Cunningham, D. *Organometallics* **1996**, 15, 4247–4257; see also Ref. 3.
  28. Shvo, Y.; Hazum, E. *Chem. Commun.* **1974**, 336–337; for examples in organoiron-mediated synthesis, see: Pearson, A. J.; Ham, P.; Ong, C. W.; Perrior, T. R.; Rees, D. C. *J. Chem. Soc., Perkin Trans. 1* **1982**, 1527–1534; Birch, A. J.; Kelly, L. F.; Weerasuria, D. V. *J. Org. Chem.* **1988**, 53, 278–281; Bandara, B. M. R.; Birch, A. J.; Kelly, L. F. *J. Org. Chem.* **1989**, 49, 4663–4763; Pearson, A. J.; O'Brien, M. K. *J. Org. Chem.* **1989**, 54, 4663–4673; Knölker, H.-J.; Baum, E.; Reddy, K. R. *Tetrahedron Lett.* **2000**, 41, 1171–1174; Knölker, H.-J.; Hopfmann, T. *Tetrahedron* **2002**, 58, 8937–8945.
  29. A trace of mesembrenone was also identified in the product.  $^1\text{H}$  NMR spectrum of mesembrenone: Jeffs, P. W.; Ahmann, G.; Campbell, H. F.; Farrier, D. S.; Ganguli, G.; Hawks, R. L. *J. Org. Chem.* **1970**, 35, 3512–3518; for  $^{13}\text{C}$  NMR data, see: Jeffs, P. W.; Capps, T.; Johnson, D. B.; Karle, J. M.; Martin, N. H.; Rauckman, B. J. *J. Org. Chem.* **1974**, 39, 2703–2710.
  30. For a discussion of *ipso* and  $\omega$  addition to multihapto  $\pi$  complexes, see Ref. 18. For the  $\omega$  directing nature of aryl substituents on cyclohexadienyliron complexes, see Ref. 3. In this case, the presence of the 4-OMe group helps overcome the natural  $\omega$  selectivity and promote the *ipso* pathway (*ipso* relative to the position of the arene). This is because the C(4) OMe is also  $\omega$  directing (see Ref. 31), and the two control effects are opposed (for definitions of the terms 'mutually reinforcing' and 'opposed' in the context of nucleophile addition to multiply substituted ligands, see Ref. 18).
  31. For examples with opposed Me and OMe groups: Pearson, A. J.; Perrior, T. R. *J. Organomet. Chem.* **1985**, 285, 253–265; Pearson, A. J.; Ham, P. *J. Chem. Soc., Perkin Trans. 1* **1983**, 1421–1425; Pearson, A. J.; Ham, P.; Rees, D. C. *J. Chem. Soc., Perkin Trans. 1* **1982**, 489–497; Tao, C.; Donaldson, W. A. *J. Org. Chem.* **1993**, 58, 2134–2143; We used a similar approach towards the terpene tridachione: Stephenson, G. R. *J. Chem. Soc., Perkin Trans. 1* **1982**, 2449–2456; Alexander, R. P.; James, T. D.; Stephenson, G. R. *J. Chem. Soc., Dalton Trans.* **1987**, 2013–2016.
  32. Roe, C.; Stephenson, G. R. *Org. Lett.*, submitted for publication.